These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7106669)

  • 21. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Physical basics and clinical realization of interstitial brachytherapy of the prostate with iodine 125].
    Kaulich TW; Lamprecht U; Paulsen F; Kahmann F; Maurer U; Henkel TO; Loeser W; Bichler KH; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2002 Oct; 178(10):548-55. PubMed ID: 12386786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The recommendations of the International Commission on Radiological Protection (ICRP) for high-dose-rate brachytherapy and for permanent prostatic implants].
    Cosset JM; Pinillos-Ashton L; Mettler F;
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S50-5. PubMed ID: 15679247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer.
    Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
    Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
    Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
    Pickett B; Pouliot J
    Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
    Cosset JM; Haie-Meder C
    Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Environmental radiation dose monitor after 125I radioactive seed implantation].
    Zhuo SQ; Chen L; Zhang FJ; Zhao M; Zhang L; Liu J; Li K; Wu PH; Zheng QS; Wang Y
    Ai Zheng; 2007 Jun; 26(6):666-8. PubMed ID: 17562278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Brachytherapy for prostate cancer].
    Yorozu A; Toya K; Ohashi T; Ohsuga K; Ito R; Kasamatsu T; Saito S; Momma T
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):424-7. PubMed ID: 16612148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation safety considerations in GliaSite 125I brain implant procedures.
    Strzelczyk J; Safadi R
    Health Phys; 2004 May; 86(5 Suppl):S120-3. PubMed ID: 15069303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Brachytherapy in the treatment of prostatic carcinoma].
    Casas F; Ferrer F; Casals J; Farrus B; Rovirosa A; Biete A
    Actas Urol Esp; 1995 Sep; 19(8):662-9. PubMed ID: 8669336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
    Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
    Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymer gel dosimetry for the TG-43 dosimetric characterization of a new 125I interstitial brachytherapy seed.
    Papagiannis P; Pantelis E; Georgiou E; Karaiskos P; Angelopoulos A; Sakelliou L; Stiliaris S; Baltas D; Seimenis I
    Phys Med Biol; 2006 Apr; 51(8):2101-11. PubMed ID: 16585848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
    Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
    Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
    Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
    Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An applicator for the implantation of I125 seeds for interstitial therapy of brain tumors].
    Bockermann V; Dieckmann G; Lott H
    Strahlenther Onkol; 1988 Mar; 164(3):148-50. PubMed ID: 3353852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Radiation resistance: a concept in need of review or a stubborn problem for radio-oncology?].
    Lütolf UM
    Schweiz Med Wochenschr; 1984 Sep; 114(36):1232-6. PubMed ID: 6385232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demystifying care of patients with radioactive implants.
    Hassey K
    Am J Nurs; 1985 Jul; 85(7):788-92. PubMed ID: 3848274
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.